WO2022124840A1 - 해삼 생식선 추출물을 포함하는 조성물, 해삼 난소 추출물로부터 유래된 화합물, 및 이의 용도 - Google Patents
해삼 생식선 추출물을 포함하는 조성물, 해삼 난소 추출물로부터 유래된 화합물, 및 이의 용도 Download PDFInfo
- Publication number
- WO2022124840A1 WO2022124840A1 PCT/KR2021/018696 KR2021018696W WO2022124840A1 WO 2022124840 A1 WO2022124840 A1 WO 2022124840A1 KR 2021018696 W KR2021018696 W KR 2021018696W WO 2022124840 A1 WO2022124840 A1 WO 2022124840A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sea cucumber
- extract
- formula
- ovary
- gonad
- Prior art date
Links
- 241000251511 Holothuroidea Species 0.000 title claims abstract description 167
- 239000000284 extract Substances 0.000 title claims abstract description 141
- 210000001672 ovary Anatomy 0.000 title claims abstract description 88
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 37
- 210000004392 genitalia Anatomy 0.000 title abstract 6
- 210000004907 gland Anatomy 0.000 title abstract 6
- 230000000694 effects Effects 0.000 claims abstract description 50
- 229930182490 saponin Natural products 0.000 claims abstract description 39
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 35
- -1 saponin compound Chemical class 0.000 claims abstract description 35
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 28
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 27
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 27
- 206010061218 Inflammation Diseases 0.000 claims abstract description 23
- 230000004054 inflammatory process Effects 0.000 claims abstract description 23
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 230000004069 differentiation Effects 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 210000002149 gonad Anatomy 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 210000001789 adipocyte Anatomy 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 37
- 238000009825 accumulation Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 13
- 230000002710 gonadal effect Effects 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000002034 butanolic fraction Substances 0.000 claims description 7
- 210000000229 preadipocyte Anatomy 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 108010016731 PPAR gamma Proteins 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 49
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- 239000003925 fat Substances 0.000 description 33
- 235000019197 fats Nutrition 0.000 description 33
- 235000017709 saponins Nutrition 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 29
- 230000035508 accumulation Effects 0.000 description 27
- 239000002609 medium Substances 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 235000012000 cholesterol Nutrition 0.000 description 16
- 230000006872 improvement Effects 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000011759 adipose tissue development Effects 0.000 description 15
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 13
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 230000002611 ovarian Effects 0.000 description 11
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 230000003579 anti-obesity Effects 0.000 description 9
- 244000309466 calf Species 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000003178 anti-diabetic effect Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002032 methanolic fraction Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960004586 rosiglitazone Drugs 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- DLNAGMLXUYEHQS-UHFFFAOYSA-N 3-O-beta-D-glucopyranosylserjanic acid Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O DLNAGMLXUYEHQS-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000000636 white adipocyte Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000965254 Apostichopus japonicus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- PALNVYHUKHRDOP-UHFFFAOYSA-N UNPD162310 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O PALNVYHUKHRDOP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009815 adipogenic differentiation Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000006377 glucose transport Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229930186900 holotoxin Natural products 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CCDRPBGPIXPGRW-JNKODXNQSA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CCDRPBGPIXPGRW-JNKODXNQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JXLPOVGRTXYUHF-UHFFFAOYSA-N 3-O-(alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl)serjanic acid 28-O-beta-D-glucopyranoside Natural products C12CC(C(=O)OC)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O JXLPOVGRTXYUHF-UHFFFAOYSA-N 0.000 description 1
- UPPXMONNNGGKMB-UHFFFAOYSA-N 3-O-(alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl)spergulagenic acid Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(CO)C(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(CC6C5=CC4)C(O)=O)C(O)=O)C)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O UPPXMONNNGGKMB-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010065459 CCAAT-Enhancer-Binding Protein-alpha Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- QIFOTGBMWFMXRC-UHFFFAOYSA-N Holotoxin A Natural products OC1C(OC)C(O)C(CO)OC1OC1C(O)C(OC2C(OCC(C2O)OC2C(C(O)C(OC3C(C(O)C(O)CO3)O)C(C)O2)O)OC2C(C3C(C=4C(C5(CC(=O)C6C5(C(OC6(CCCC(C)(C)O)C)=O)CC=4)C)CC3)(C)CC2)(C)C)OC(CO)C1O QIFOTGBMWFMXRC-UHFFFAOYSA-N 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- RGDJCYRXKJVXKD-UHFFFAOYSA-N Saponin 3 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(C)C5CCC34C)C2C1)C(=O)O RGDJCYRXKJVXKD-UHFFFAOYSA-N 0.000 description 1
- ZMUQGGLSCIDPLS-UHFFFAOYSA-N Saponin 5 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C(C)(C)C5CCC34C)C2C1)C(=O)O ZMUQGGLSCIDPLS-UHFFFAOYSA-N 0.000 description 1
- AOILXFWEUKCKQQ-UHFFFAOYSA-N Saponin 8 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O AOILXFWEUKCKQQ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- WCMJLEULXWUCRF-UHFFFAOYSA-N emarginatoside B Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WCMJLEULXWUCRF-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- BIHNZKYXOTXXSP-GCBHNEMQSA-N holotoxin a Chemical compound O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](OC)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@@H](C)O3)O)[C@H](OC3C(C4[C@](C=5C([C@@]6(CC(=O)[C@H]7C6(C(O[C@]7(CCCC(C)=C)C)=O)CC=5)C)CC4)(C)CC3)(C)C)OC2)O)O[C@H](CO)[C@H]1O BIHNZKYXOTXXSP-GCBHNEMQSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004053 pancreatic β cell dysfunction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
Definitions
- the present invention relates to a novel use of a sea cucumber gonad extract, preferably a use of the sea cucumber gonad extract to improve anti-obesity, anti-diabetes, dyslipidemia, and/or inflammatory diseases, a novel compound isolated from the sea cucumber gonad extract, or the compound It relates to the use of, preferably anti-obesity, anti-diabetes, dyslipidemia improvement, and/or inflammatory disease improvement use.
- Sea cucumber ( Stichopus japonicus ) is a traditional seafood used as an important ingredient in Asian countries, especially China, Japan and Korea. There are many bioactive substances isolated from sea cucumber. In particular, collagen peptides and polysaccharides are well known to exhibit various biological activities. The ovaries of sea cucumbers are called sea cucumbers and are famous for their delicacies.
- adipocytes lipid metabolism occurs through lipolysis and adipogenesis, and during fat synthesis, the preadipocytes undergo proliferation and differentiation processes to differentiate into mature adipocytes. This leads to the accumulation of fat in the cells.
- transcription factors inducing the differentiation process of adipocytes peroxisome proliferator activated receptor ⁇ (PPAR ⁇ ) and CCAAT enhancer binding protein ⁇ (C/EBPa) have been reported. Expression of the transcription factors is induced at different time points in the process of adipocyte differentiation, and through interaction with each other, the expression of adipocyte-specific genes is controlled, and fat metabolism is activated and adipocyte differentiation is gradually induced. They are known to be involved in lipogenesis and adipogenesis leading to obesity.
- Dyslipidemia is a disease name that includes hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. This is a state in which total cholesterol, LDL cholesterol, and triglycerides in the blood are increased or HDL cholesterol is decreased. Dyslipidemia is diagnosed if at least one of these is found in the blood test for total cholesterol below 200 mg/dL, LDL cholesterol below 130 mg/dL, HDL cholesterol above 60 mg/dL, and triglyceride below 150 mg/dL. Diagnosis of dyslipidemia is based on the universally accepted American National Cholesterol Education Program (NCEP), total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL). ) is diagnosed through lipid indicators such as cholesterol and triglyceride.
- NCEP National Cholesterol Education Program
- Type 2 diabetes mellitus is a metabolic disease characterized by insulin resistance, pancreatic beta-cell dysfunction, and consequent rise in blood sugar, and the occurrence of the disease shows a complex genetic tendency.
- PPAR ⁇ Peroxisome proliferator-activated receptor-gamma
- PPAR ⁇ is a gene thought to be important in relation to insulin resistance.
- PPAR ⁇ is specific to adipocytes, is involved in adipocyte differentiation and fatty acid metabolism, and thiazolidinediones, an antidiabetic drug, is known as a ligand.
- PPAR ⁇ a lipid-activating transcription factor
- PPAR ⁇ has several functions in the immune system, and it is known that it can regulate inflammation and anti-inflammatory responses through inhibition of this transcription factor, and it is known that it is involved in the treatment of inflammatory bowel disease and rheumatoid arthritis.
- PPAR ⁇ in immunity and inflammation cell types and diseases, Biochimica et Biophysica Acta 1771 (2007) 1014 - 1030).
- the problem to be solved by the present invention is to provide a new compound isolated from sea cucumber, in particular, a saponin compound.
- the problem to be solved by the present invention is a sea cucumber gonad extract, preferably an ovarian extract, anti-obesity, anti-diabetes, dyslipidemia improvement, and/or inflammatory disease improvement of a saponin compound derived from the extract for preventing or treating diseases We want to provide new uses.
- it is intended to provide a composition for treating or preventing obesity, diabetes, or inflammatory disease comprising a sea cucumber gonad extract, or a saponin compound derived from the extract.
- the present invention provides a novel compound represented by the following Chemical Formulas S1, S2, S3, S4 and/or S9.
- the compound may be derived from nature or may be synthesized by a chemical synthesis method, and the process for obtaining the compound is not particularly limited.
- the compound may be extracted or isolated from the gonads of sea cucumbers, preferably extracted or isolated from the ovaries of sea cucumbers.
- Another embodiment of the present invention includes a sea cucumber gonad extract, or a saponin compound derived from sea cucumber gonad as an active ingredient, prevention of any one or more diseases selected from the group consisting of obesity, diabetes, dyslipidemia, and / or inflammation
- a therapeutic composition is provided.
- the diabetes may be type 2 diabetes.
- the sea cucumber ovary extract means that the ovary, which is the reproductive organ of sea cucumber, is extracted with a solvent.
- a solvent As the gonads of sea cucumbers mature, it is known that the testes turn milky white and the ovaries turn red.
- the solvent water, C1 to C4 lower alcohol, or a mixed solvent thereof may be used.
- ethanol or an aqueous ethanol solution is used.
- the solvent when the solvent is used, the extraction yield of the active ingredient is excellent and may be advantageous in achieving the object of the present invention.
- the extract of the present invention may be prepared according to a conventional method for producing an extract for an animal, and specifically may be a cold extraction method, a hot extraction method, or a heat extraction method.
- a fractionator may be used.
- the sea cucumber gonad extract preferably the ovary extract
- the sea cucumber ovary extract can be extracted with a 45 to 85% (V/V) aqueous ethanol solution as a solvent, and more preferably, the sea cucumber ovary with a 48 to 55% (V/V) aqueous ethanol solution as a solvent.
- V/V aqueous ethanol solution
- 75 to 83% (V/V) aqueous ethanol solution may be extracted as a solvent.
- the sea cucumber gonad may undergo a process of fractionating the extract, and the sea cucumber ovary fraction obtained therefrom may also be included in the scope of the present invention.
- the extract obtained by extracting sea cucumber ovaries with an aqueous ethanol solution may be fractionated, and preferably, the aqueous ethanol solution may be 45 to 85% (V/V) aqueous ethanol solution.
- the fraction may be fractionated from the sea cucumber ovary extract using butanol as a solvent. The fraction can be obtained by suspending the sea cucumber ovary extract in distilled water, etc. and then using a separatory funnel, etc.
- the sea cucumber ovary extract can be fractionated with butanol.
- the fractionation may be carried out by a fractionation method commonly used in the art.
- the prepared extract or the fraction obtained by performing the fractionation process may then be filtered or concentrated or dried to remove the solvent, and both filtration, concentration and drying may be performed.
- the filtration may use filter paper or a reduced pressure filter, and the concentration may be concentrated under reduced pressure using a reduced pressure concentrator, for example, a rotary evaporator, and the drying may be performed by, for example, a freeze drying method.
- the extract or fraction may have an excellent body fat reduction effect, an excellent adipocyte differentiation inhibitory activity, an excellent inflammation improvement effect, an excellent cholesterol reduction effect, and an excellent diabetes treatment or improvement effect. .
- the sea cucumber gonad preferably the ovary extract
- the following compounds isolated from the dissolved ovarian extract may have therapeutic or preventive effects on any one or more diseases selected from the group consisting of obesity, inflammation, diabetes, and dyslipidemia.
- the saponin compound derived from the sea cucumber gonadal, preferably ovarian extract, or sea cucumber ovary is PPAR ⁇ (Peroxisome proliferation activated receptor- ⁇ ), FAS (FS-7-associated surface antigen), aP2 (Adipocyte protein 2), and C/EBPa (CCAAT/Enhancer-binding Protein ⁇ ) expression can be inhibited with any one or more proteins selected from the group consisting of.
- the saponin compound derived from sea cucumber gonadal, preferably ovarian extract, or sea cucumber ovary can inhibit the differentiation of preadipocytes into adipocytes, or inhibit intracellular fat accumulation. Or it may have a diabetes inhibitory effect.
- the saponin compound derived from the sea cucumber gonad preferably an ovary extract, or sea cucumber ovary is used for weight loss, blood abnormal lipid reduction, lipid metabolism abnormality alleviation, etc., for inhibiting or improving inflammation, or for treating diabetes Or it can be used for the purpose of improvement.
- a saponin compound derived from sea cucumber gonad, preferably ovary, or a sea cucumber ovary is treated to an individual in need thereof to suppress, improve or alleviate body fat accumulation, lose weight, or blood abnormalities
- a method for reducing lipid or inhibiting body fat accumulation in a subject, a method for ameliorating or inhibiting inflammation, or a method for treating or ameliorating diabetes may be provided.
- One embodiment of the present invention is a composition for inhibiting body fat accumulation in an individual, comprising the following steps: a composition for treating or improving dyslipidemia in an individual, a composition for treating or improving an individual's inflammation-related disease, or diabetes treatment or A method for preparing a composition for improvement can be provided.
- step S2) treating the gonads of the sea cucumber separated in step S1) with a solvent, preferably with an ethanol solvent, more preferably with a 45 to 85% (V/V) aqueous ethanol solution, and dosing;
- a solvent preferably with an ethanol solvent, more preferably with a 45 to 85% (V/V) aqueous ethanol solution, and dosing;
- One embodiment of the present invention is a food or drug for improving or treating obesity comprising the gonad extract of sea cucumber disclosed herein, a food or drug for improving or treating diabetes (especially type 2 diabetes), dyslipidemia (eg, Hyperlipidemia, hypercholesterolemia, hypertriglyceridemia) improvement or treatment food or medicine, inflammation (eg, inflammatory bowel disease, rheumatoid arthritis) improvement or treatment food or medicine can be provided.
- dyslipidemia eg, Hyperlipidemia, hypercholesterolemia, hypertriglyceridemia
- inflammation eg, inflammatory bowel disease, rheumatoid arthritis
- the food or drug may include, without limitation, excipients, additives, and the like generally used in the industry in a range that does not impair the purpose of the present invention.
- One embodiment of the present invention may provide a method for inhibiting the expression of any one or more proteins selected from the group consisting of PPAR ⁇ , FAS, aP2, and C/EBPa in an individual in need thereof by treating the sea cucumber ovary extract.
- the composition according to an embodiment of the present invention is selected from the group consisting of obesity, inflammation, diabetes, and dyslipidemia of the saponin compound derived from the sea cucumber gonad, preferably ovarian extract, or sea cucumber gonad, preferably ovary of the present invention.
- Any one or more diseases may be used without limitation as long as the field can be applied to a novel use for treatment, prevention, and/or improvement, etc., and may preferably be provided in the form of a pharmaceutical composition or a food composition.
- the food composition may be provided as a health functional food composition.
- the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, methyl cellulose, methylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.
- the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
- the pharmaceutical carrier is a non-limiting example, and is not limited to the above type.
- the pharmaceutical composition of the present invention may be administered orally or parenterally, and is preferably applied by oral administration.
- a suitable dosage of the pharmaceutical composition of the present invention is variously prescribed depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity of the patient.
- a preferred dosage of the pharmaceutical composition of the present invention is within the range of 0.001-100 mg/kg for adults.
- the pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by a person of ordinary skill in the art to which the present invention pertains. or it may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension, syrup, or emulsion in oil or an aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.
- the composition of the present invention when prepared as a food composition, it includes ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents.
- the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- a natural flavoring agent such as stevia extract or a synthetic flavoring agent such as saccharin may be used.
- any one or more saponin compounds selected from the group consisting of Formula S1, S2, S3, S4, S5, S6, S8 and S9, preferably S3, S4, S5, S6 and S8 It provides a method of improving the prevention or treatment effect of any one or more diseases selected from the group consisting of obesity, anti-inflammatory, diabetes, and dyslipidemia of sea cucumber gonadal, preferably ovarian extract, by increasing any one or more saponin compounds selected from .
- All of the methods for obtaining the saponin compound mentioned in the present invention can be used, and preferably, the method is used as a method of extracting sea cucumber gonads, preferably ovaries with an aqueous ethanol solution, and obtaining a butanol fraction from the extract, Preferably, extraction with 45 to 85% (V/V) aqueous ethanol solution, and a method of fractionating butanol from the extract may be used.
- One embodiment of the present invention is from the group consisting of obesity, inflammation, diabetes, and dyslipidemia, comprising administering an effective amount of a saponin compound derived from the gonad extract of sea cucumber or sea cucumber gonad to an individual in need thereof
- a method for treating or ameliorating any one selected disease is provided.
- the saponin compound derived from the germline of sea cucumber mentioned herein includes any one or more selected from the group consisting of Formulas S1, S2, S3, S4, S5, S6, S8 and S9.
- Another embodiment treats or improves any one disease selected from the group consisting of obesity, inflammation, diabetes, and dyslipidemia that increases the saponin compound derived from the gonad extract of sea cucumber or the gonad of sea cucumber in an individual in need thereof can provide a way to Another embodiment is the treatment of any one disease selected from the group consisting of obesity, inflammation, diabetes, and dyslipidemia, comprising a gonad extract of sea cucumber, or a saponin compound derived from the gonad of sea cucumber and a pharmaceutically acceptable carrier Or it may provide a composition for improvement.
- Another embodiment may provide a use for treating or ameliorating any one disease selected from the group consisting of obesity, inflammation, diabetes, and dyslipidemia of a gonad extract of sea cucumber, or a saponin compound derived from the gonad of sea cucumber.
- Another embodiment is any one selected from the group consisting of PPAR ⁇ , FAS, aP2, and C/EBPa in the body, comprising administering to an individual in need thereof an effective amount of a gonad extract of sea cucumber, or a saponin compound derived from the gonad of sea cucumber
- Methods of inhibiting expression of one or more proteins may be provided.
- the present invention provides a novel saponin compound not previously known.
- the present invention proposes a novel use of a sea cucumber gonadal, preferably ovarian extract or a saponin compound isolated therefrom.
- the sea cucumber gonad preferably the ovary extract
- 1 is a result of confirming the cell viability after treating 3T3-L1 cells with a sea cucumber ovary extract and an extract obtained by varying the ethanol concentration of intestines except for the ovaries.
- Figure 2a is a diagram showing the effect of a sea cucumber extract on adipocyte differentiation and fat accumulation inhibition.
- Figure 2b shows O.D. represents a value.
- Figure 3 shows the results of analysis of genes and proteins related to adipocyte differentiation by region and concentration of sea cucumber extract.
- Figure 3a is a result showing the protein expression level
- the graph of Figure 3b is the result of confirming the effect of the sea cucumber extract on mRNA expression.
- Figure 4a is a photograph showing the differentiation of adipocytes of the sea cucumber extract
- Figure 4b is a graph showing the fat accumulation inhibitory effect (25, 50 ⁇ g / ml).
- FIG. 6 is a diagram showing the process of isolating the compound through the extraction and fractionation of the sea cucumber ovary extract.
- Figure 8 shows the results of analyzing the degree of fat accumulation through Oil red O staining after the completion of adipogenic differentiation of 3T3-L1 cells for compounds isolated from sea cucumber ovary extract.
- (b) shows differentiated 3T3-L1 cells
- (c) shows the optical density (OD) of Oil Red O measured at 500 nm. 2.5 and 5 ⁇ g/ml concentrations were treated, respectively.
- Figure 14 shows the final body weight confirmed after the extract treatment of high-calorie diet intake rats.
- Sea cucumbers were extracted by dividing the ovaries and intestines except for the ovaries, and 50% ethanol and 80% ethanol were added 20 times each to the dried sea cucumber ovaries and intestines, respectively, and extracted by stirring at room temperature for 24 hours. Thereafter, sea cucumber ovary and intestine extracts were obtained through filtration and concentration under reduced pressure.
- Reagents and materials are as follows.
- 3T3-L1 cells ATCC, CL-173
- DMEM high glucose (Gibco) fetal bovine serum
- Gibco penicillin-streptomycin-glutamin
- phosphate buffered saline (Gibco) Radioimmunoprecipitation assay (RIPA) buffer (Thermo) scientific), protease- and phosphatase-inhibitor cocktails (Thermo scientific), PVDF membrane (Bio-rad), Primary antibody (PPAR ⁇ (Santa cruz), C/EBPa (cell signaling), FAS (cell signaling), aP2 (cell signaling) ), ⁇ -actin (Santa cruz), Oli red O powder (sigma), and MTT powder (sigma) were used.
- PPAR ⁇ Santa cruz
- C/EBPa cell signaling
- FAS cell signaling
- aP2 cell signaling
- ⁇ -actin Oli red O powder
- MTT powder MTT powder
- 3T3-L1 cells were aliquoted in a 96-well plate at a concentration of 1x10 4 cells/well, cultured for one day, and 6 extracts were treated at a concentration of 100-200 ⁇ g/ml. After 24 hours, MTT powder was dissolved in PBS at a concentration of 5 mg/ml, filtered, and 20 ⁇ l of each cell was dispensed and cultured for 2 hours. After removing the medium, 200 ⁇ l of DMSO was dispensed, and absorbance was measured at 570 nm to measure cell viability.
- 3T3-L1 cells were cultured in high glucose DMEM medium supplemented with 10% calf serum and penicillin streptomycin glutamin, and subcultured every 2-3 days. 3T3-L1 cells were aliquoted in a 6 well plate at a concentration of 4x10 5 cells/well and cultured for 2 days. Then, dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum. ) was replaced with the added MDI medium. After 2 days, the medium was replaced with insulin, and the medium was replaced every 2 days to induce differentiation. The sea cucumber extract was treated at a concentration of 200 ⁇ g/ml 30 minutes after medium replacement.
- IBMX 3-isobuty-1-methylxanthine
- 3T3-L1 cells were fixed with 4% formaldehyde for 1 hour, and then the degree of differentiation was confirmed by staining the fat using a 0.5% Oil red O staining solution.
- absorbance was measured at 500 nm by dissolving the dye dyed in cells with 100% isopropyl alcohol.
- RNA expression level of the related genes was confirmed using qRT-PCR.
- 3T3-L1 cells were harvested using PBS and extracted using Rneasy Mini kit (Qiagen).
- the extracted RNA was 1 ⁇ g cDNA (ReverTra Ace qPCR RT Master Mix, FSQ-201, TOYOBO) was synthesized and SYBR RT-PCR was performed in the green method.
- PCR conditions were 40 cycles of pre-denaturation (95°C, 1 min), 95°C, 15 sec, and 60°C, 15 sec.
- the primer sequences used are shown in Table 2.
- FIG. 1 The viability of 3T3-L1 cells after sea cucumber extract treatment is shown in FIG. 1 .
- the degree of fat accumulation was analyzed through Oil red O staining. It showed the effect of reducing fat accumulation.
- the absorbance was measured by dissolving Oil red O dyed in the cells with 100% isopropyl alcohol. It was confirmed that the accumulation was reduced.
- the sea cucumber ovary extract had a significant fat accumulation inhibitory effect compared to other organs of the sea cucumber.
- treatment groups 3 and 4 ovarian extract
- O.D O.D.
- the value was only about half that of treatment groups 1 and 2.
- sea cucumber extract inhibits fat differentiation by regulating the expression of genes and proteins related to fat differentiation.
- 3 shows the results of suppressing the expression of fat differentiation-related genes and proteins of the sea cucumber extract.
- the best extraction conditions are sea cucumber ovary 50% (Sample name: SJ-O-D1-50) or 80% ethanol extract (Sample name: SJ- O-D1-80). That is, treatment groups 3 and 4 were excellent in inhibiting gene expression related to adipogenesis.
- Sample name extract information One SJ-O-D1-30 Dry ovary 30% EtOH, 20 times, 24h stirring, primary extraction 2 SJ-O-D1-50 Dry ovary 50% EtOH, 20 times, 24h stirring, 1st extraction 3 SJ-O-D1-80 Dry ovary 80% EtOH, 20 times, 24h stirring, 1st extraction 4 SJ-O-D1-H hexane fraction of sample 2 5 SJ-O-D1-B Sample 2 BuOH fraction
- 3T3-L1 cells were cultured in high glucose DMEM medium supplemented with 10% calf serum and penicillin streptomycin glutamin, and subcultured every 2-3 days. 3T3-L1 cells were aliquoted in a 6 well plate at a concentration of 4x10 5 cells/well and cultured for 2 days. Then, dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum. ) was replaced with the added MDI medium, and the sea cucumber extract was treated 30 minutes after the replacement of the MDI medium. After 2 days, the medium was replaced with an insulin-containing medium, and a new medium was replaced every 2 days to induce differentiation.
- dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum.
- IBMX 3-isobuty-1-methylxanthine
- 3T3-L1 cells were fixed with 4% formaldehyde for 1 hour, and then the degree of differentiation was confirmed by staining the fat using a 0.5% Oil red O staining solution.
- absorbance was measured at 500 nm by dissolving the dye dyed in cells with 100% isopropyl alcohol.
- Ethanol extracts were obtained by extracting the intestines and ovaries of sea cucumber except for the ovaries, respectively, as follows. After adding 30% EtOH, 50% EtOH, or 80% EtOH to the dried sea cucumber ovary in 20 folds, the mixture was stirred for 24 hours, filtered in the same way, and then concentrated.
- the fractions of the sea cucumber ovary extract were obtained in the following way.
- each sea cucumber extract was treated with a differentiation medium at a concentration of 25 and 50 ⁇ g/ml (Sample 6, 10, 25 ⁇ g/ml) for 48 hours. So the experiment was carried out. As a result of analyzing the degree of fat accumulation through Oil red O staining, all samples except sample 1 showed a significant fat accumulation inhibitory effect. (Fig. 4)
- the separation/purification method is shown in FIG. 6 .
- a specific separation/purification method is as follows.
- each single compound was treated at a concentration of 2.5 - 5 ⁇ g/ml to check cell viability. As a result, the majority of samples showed no significant change. could check Samples of S3, S4, and S5 showed a significant decrease at a concentration of 2.5 ⁇ g/ml, but showed a cell viability of about 80% or more.
- Samples of S3 suppressed about 16, 40, and 80% fat accumulation from 1 ⁇ g/ml to 5 ⁇ g/ml, and showed a tendency to have a concentration-dependent inhibitory effect on adipogenesis, while samples of S4-S8 showed differentiation at 2.5 ⁇ g/ml. It was confirmed that fat accumulation was suppressed at the level of cells that were not treated.
- Tables 4 to 9 below show the results of 13 C and 1 H NMR chemical shifts of S1-S4 and S9 of the compounds isolated from the sea cucumber ovary extract. Through this, it was confirmed that S1-S4 and S9 were newly isolated saponin compounds.
- 3T3-L1 cells ATCC, CL-173
- DMEM high glucose Welgene
- Fetal bovine serum MPBio
- penicillin-streptomycin Welgene
- Dulbecco's phosphate-buffered saline Welgene
- Trypsin-EDTA Welgene
- Bovine calf serum Welgene
- Glucose Uptake-Glo Assay Kit Promega
- 3T3-L1 cells were cultured in high glucose DMEM medium supplemented with 10% Calf serum and penicillin-streptomycin, and subcultured every 2-3 days. 3T3-L1 cells were aliquoted in a 96-well plate at a concentration of 2x10 4 cells/well and cultured for 3 days. Then, dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum. It was replaced with the added MDI medium. After 2 days, the medium was replaced with insulin, and the medium was replaced every 2 days to induce differentiation.
- dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum. It was replaced with the added MDI medium. After 2 days, the medium was replaced with insulin, and the medium was replaced every 2 days to induce differentiation.
- 3T3-L1 cells were subjected to stavation for 16 hours, and then treated with sea cucumber extract at concentrations of 25 and 50 ug/mL in serum-free medium for 6 hours. The culture supernatant was recovered and the glucose transport activity was measured using a luminometer in 3T3-L1 cells using the Glucose Uptake-Glo Assay Kit.
- the intracellular glucose uptake rate of the sea cucumber ovary extract is remarkably excellent.
- 10 is a result of confirming the glucose absorption rate of the sea cucumber ovary extract and the intestine extract excluding the ovary of sea cucumber.
- 11 is a result of confirming the glucose absorption rate for each extraction condition of the sea cucumber ovary extract.
- Glucose absorption rate was excellent compared to the control group at all concentrations. In particular, it was confirmed that it has a higher glucose absorption efficiency than Rosiglitazone, which is used as a diabetes treatment, and it was found that the sea cucumber ovary extract has an excellent antidiabetic effect.
- the sea cucumber ovary extract increased the glucose absorption rate compared to the untreated group, and in particular, compared to the 1.24-fold increase in Rosiglitazone, the sea cucumber ovary extract had a much higher absorption rate (1.29 times, 1.43 times, 1.35 times).
- 3T3-L1 cells were cultured in high glucose DMEM medium supplemented with 10% Calf serum and penicillin-streptomycin, and subcultured every 2-3 days. 3T3-L1 cells were aliquoted in a 96-well plate at a concentration of 2x10 4 cells/well and cultured for 3 days. Then, dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum. It was replaced with the added MDI medium. After 2 days, the medium was replaced with insulin, and the medium was replaced every 2 days to induce differentiation.
- dexamethasone, insulin, and 3-isobuty-1-methylxanthine (IBMX) were added to a medium containing 10% FBS instead of calf serum. It was replaced with the added MDI medium. After 2 days, the medium was replaced with insulin, and the medium was replaced every 2 days to induce differentiation.
- 3T3-L1 cells were treated with a single compound derived from sea cucumber at a concentration of 2.5 ug/mL in a serum-free medium for 6 hours after stavation for 16 hours.
- the culture supernatant was recovered and the glucose transport activity was measured using a luminometer in 3T3-L1 cells using the Glucose Uptake-Glo Assay Kit.
- FIG. 12 is a result of confirming the glucose absorption rate of the saponin compounds isolated from the ovarian extract of sea cucumber. As can be seen in FIG. 12 , when the glucose absorption rate of the untreated group was 100%, all compounds showed an absorption rate of 100% or more. Through these results, it was found that the isolated compounds increased the glucose absorption rate compared to the untreated group, and each had an antidiabetic effect.
- Table 11 is a fold change value showing the degree of glucose uptake compared to the control group. It also showed a similar level of glucose uptake as that of rosiglitazone.
- mice in each group were tested. Except for the normal diet group, all groups were fed a high-fat diet.
- the extract was fed through a diet by preparing a feed, and the experiment was conducted for 8 weeks. Body weight was measured once a week, and dietary intake was measured three times a week.
- 13 and 14 are results of observing the weight change and finally confirmed body weight of rats ingesting a high-calorie diet.
- the group treated with the sea cucumber ovary extract (50% ethanol) confirmed that up to 8 weeks, the weight gain was significantly reduced compared to the untreated group.
- the final body weight decreased when compared to the HFD-labeled sea cucumber ovary extract untreated group.
- Hematoxilin is a basic/cationic substance that stains the nucleus (anion) in dark blue or purple, and eosin is an acidic/anionic substance that stains the cytoplasm (cation) in red or pink.
- HDL/TC High-density lipoprotein content compared to total cholesterol in blood
- HDL-C(mg/dl) (absorbance of sample/absorbance of standard) x 100(mg/dl)
- test tubes for blind/standard/sample respectively.
- Total cholesterol (mg/dl) (absorbance of sample/absorbance of standard) x concentration of standard solution
- test tubes for blind/standard/sample respectively.
- Triglyceride mass (mg/dl) (absorbance of sample / absorbance of standard) x 300 (mg/dl)
- the present invention may provide a composition for weight loss, an anti-obesity composition, an anti-diabetic composition, an anti-inflammatory composition, and a composition for improving dyslipidemia, which include a sea cucumber ovary extract.
- the composition of the present invention may provide a method for weight loss, a method for suppressing obesity, a method for treating or improving diabetes, a method for treating or improving inflammation, and a method for treating or improving dyslipidemia.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
부위 | 용매 | ||
해삼 (Stichopus japonicus) | 내장 | 1 | 50% EtOH |
2 | 80% EtOH | ||
난소 | 3 | 50% EtOH | |
4 | 80% EtOH |
Gene | Forward primer (5'→3') | Reverse primer (5'→3') |
C/EBPα | 서열번호 1 | 서열번호 2 |
PPARγ | 서열번호 3 | 서열번호 4 |
FAS | 서열번호 5 | 서열번호 6 |
aP2 | 서열번호 7 | 서열번호 8 |
β-Actin | 서열번호 9 | 서열번호 10 |
시료명 | 추출물 정보 | |
1 | SJ-O-D1-30 | 건조된 난소 30% EtOH, 20배수, 24h 교반, 1차 추출 |
2 | SJ-O-D1-50 | 건조된 난소 50% EtOH, 20배수, 24h 교반, 1차 추출 |
3 | SJ-O-D1-80 | 건조된 난소 80% EtOH, 20배수, 24h 교반, 1차 추출 |
4 | SJ-O-D1-H | 시료 2의 hexane 분획 |
5 | SJ-O-D1-B | 시료 2 BuOH 분획 |
Sample | Fold change |
Rosiglitazone (Ref.) | 1.24 |
30% EtOH | ~1.29 |
50% EtOH | ~1.43 |
80% EtOH | ~1.35 |
Sample | Fold Relative to Control |
Rosiglitazone (Ref.) | 1.49 |
S1 | 1.25 |
S2 | 1.43 |
S3 | 1.1 |
S4 | 1.6 |
S5 | 1.38 |
S6 | 1.24 |
S8 | 1.43 |
S9 | 1.03 |
Claims (13)
- 제1항에 있어서, 상기 화합물은 해삼의 난소로부터 추출 또는 분리된 것을 특징으로 하는 화합물.
- 해삼의 생식선 추출물, 또는 해삼의 생식선으로부터 유래된 사포닌 화합물을 유효성분으로 포함하는, 비만, 염증, 당뇨병, 및 이상지질혈증으로 이루어진 군에서 선택된 어느 하나의 질환 예방 또는 치료용 조성물.
- 제3항에 있어서, 상기 해삼의 생식선은 해삼의 난소인 것을 특징으로 하는 조성물.
- 제3항에 있어서, 상기 해삼 생식선 추출물은 해삼 생식선을 45 내지 85%(V/V) 에탄올 수용액을 용매로 추출한 것을 특징으로 하는 조성물.
- 제5항에 있어서, 상기 해삼 생식선 추출물은 해삼 생식선을 48 내지 55%(V/V) 에탄올 용매로 추출한 것을 특징으로 하는 조성물.
- 제3항에 있어서, 상기 해삼 생식선 추출물은 해삼 생식선을 48 내지 55%(V/V) 에탄올 수용액으로 추출한 추출물을 부탄올을 용매로 하여 분획한 부탄올 분획물인 것을 특징으로 하는, 조성물.
- 제3항에 있어서, 상기 해삼 생식선 추출물, 또는 해삼 생식선으로부터 유래된 사포닌 화합물은 PPARγ, FAS, aP2, 및 C/EBPα로 이루어진 군에서 선택된 어느 하나 이상의 단백질 발현을 억제하는 것을 특징으로 하는 조성물.
- 제3항에 있어서, 상기 해삼 생식선 추출물, 또는 해삼 생식선으로부터 유래된 사포닌 화합물은 지방전구세포에서 지방세포로의 분화를 억제하거나, 세포 내 지방축적을 억제하는 것을 특징으로 하는 조성물.
- 제11항에 있어서, 상기 해삼 생식선 추출물은 해삼 난소 추출물인 것을 특징으로 하는 해삼 생식선 추출물의 비만, 염증, 당뇨병, 및 이상지질혈증으로 이루어진 군에서 선택된 어느 하나 이상의 질환의 예방 또는 치료 효과를 개선하는 방법.
- 제11항에 있어서, 상기 방법은 해삼 난소를 48 내지 55%(V/V) 에탄올 수용액으로 추출하고, 추출물로부터 부탄올 분획을 획득하는 것을 특징으로 하는, 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180089989.6A CN116829568A (zh) | 2020-12-10 | 2021-12-09 | 包含海参生殖腺提取物、来源于海参卵巢提取物的化合物的组合物及其用途 |
US18/266,396 US20240058392A1 (en) | 2020-12-10 | 2021-12-09 | Composition comprising sea cucumber genital gland extract, compound derived from sea cucumber ovary extract, and use thereof |
JP2023559958A JP2024503538A (ja) | 2020-12-10 | 2021-12-09 | ナマコ生殖腺抽出物を含む組成物、ナマコ卵巣抽出物から由来した化合物、及びその用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0172701 | 2020-12-10 | ||
KR20200172701 | 2020-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022124840A1 true WO2022124840A1 (ko) | 2022-06-16 |
Family
ID=81974555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/018696 WO2022124840A1 (ko) | 2020-12-10 | 2021-12-09 | 해삼 생식선 추출물을 포함하는 조성물, 해삼 난소 추출물로부터 유래된 화합물, 및 이의 용도 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240058392A1 (ko) |
JP (1) | JP2024503538A (ko) |
KR (2) | KR102519208B1 (ko) |
CN (1) | CN116829568A (ko) |
WO (1) | WO2022124840A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090089955A (ko) * | 2008-02-20 | 2009-08-25 | 강릉원주대학교산학협력단 | 해삼의 건조분말 또는 추출물을 유효성분으로 함유하는고지혈증의 예방 및 치료용 조성물 |
KR20090089954A (ko) * | 2008-02-20 | 2009-08-25 | 강릉원주대학교산학협력단 | 해삼의 건조분말 또는 추출물을 유효성분으로 함유하는당뇨병의 예방 및 치료용 조성물 |
CN102224924A (zh) * | 2011-04-27 | 2011-10-26 | 中国海洋大学 | 含有海参皂苷的组合物及其在食品药品中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110338367A (zh) * | 2018-04-08 | 2019-10-18 | 于明志 | 一种人工方式将海参性腺注入海参体内的海参产品加工方法 |
-
2021
- 2021-12-09 KR KR1020210176129A patent/KR102519208B1/ko active IP Right Grant
- 2021-12-09 US US18/266,396 patent/US20240058392A1/en active Pending
- 2021-12-09 JP JP2023559958A patent/JP2024503538A/ja active Pending
- 2021-12-09 CN CN202180089989.6A patent/CN116829568A/zh active Pending
- 2021-12-09 WO PCT/KR2021/018696 patent/WO2022124840A1/ko active Application Filing
-
2022
- 2022-11-22 KR KR1020220157750A patent/KR20220165675A/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090089955A (ko) * | 2008-02-20 | 2009-08-25 | 강릉원주대학교산학협력단 | 해삼의 건조분말 또는 추출물을 유효성분으로 함유하는고지혈증의 예방 및 치료용 조성물 |
KR20090089954A (ko) * | 2008-02-20 | 2009-08-25 | 강릉원주대학교산학협력단 | 해삼의 건조분말 또는 추출물을 유효성분으로 함유하는당뇨병의 예방 및 치료용 조성물 |
CN102224924A (zh) * | 2011-04-27 | 2011-10-26 | 中国海洋大学 | 含有海参皂苷的组合物及其在食品药品中的应用 |
Non-Patent Citations (2)
Title |
---|
RAMALHO ALAN, LEBLANC NADINE, FORTIN MARIE-GIL, MARETTE ANDRÉ, TCHERNOF ANDRÉ, JACQUES HÉLÈNE: "Characterization of a Coproduct from the Sea Cucumber Cucumaria frondosa and Its Effects on Visceral Adipocyte Size in Male Wistar Rats", MARINE DRUGS, vol. 18, no. 11, 26 October 2020 (2020-10-26), pages 530, XP055941755, DOI: 10.3390/md18110530 * |
SILCHENKO ALEXANDRA S.; KALINOVSKY ANATOLY I.; AVILOV SERGEY A.; ANDRYJASCHENKO PELAGEYA V.; DMITRENOK PAVEL S.; YURCHENKO EKATERI: "Cladolosides O, P, P1-P3and R, triterpene glycosides with two novel types of carbohydrate chains from the sea cucumberCladolabes schmeltzii. Inhibition of cancer cells colony formation and its synergy with radioactive irradiation", CARBOHYDRATE RESEARCH, PERGAMON, GB, vol. 468, 9 August 2018 (2018-08-09), GB , pages 73 - 79, XP085467613, ISSN: 0008-6215, DOI: 10.1016/j.carres.2018.08.004 * |
Also Published As
Publication number | Publication date |
---|---|
US20240058392A1 (en) | 2024-02-22 |
JP2024503538A (ja) | 2024-01-25 |
KR20220082769A (ko) | 2022-06-17 |
KR20220165675A (ko) | 2022-12-15 |
KR102519208B1 (ko) | 2023-04-06 |
CN116829568A (zh) | 2023-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012148247A2 (ko) | 올레아놀린산 아세테이트를 유효성분으로 포함하는 tlr 및 il-6 매개성 질환예방 또는 치료용 약학적 조성물 | |
WO2013089402A1 (ko) | 돌외의 지페노사이드 추출물을 포함하는 제2형 당뇨병, 비만 또는 고지혈증의 치료 또는 예방용 조성물 | |
WO2022035115A1 (ko) | 오리나무 추출물 또는 이로부터 분리된 화합물을 함유하는 골격근 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2021010715A1 (ko) | 골질환 예방 또는 치료용 약학 조성물 | |
WO2016080796A2 (ko) | 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
WO2012067316A1 (ko) | 테로카판계 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 대사성 질환 또는 이들의 합병증의 예방 또는 치료용, 또는 항산화용 조성물 | |
WO2014175543A1 (ko) | 복합 추출물을 포함하는 대장염 예방, 개선 또는 치료용 조성물 | |
WO2014027832A1 (ko) | 대장염 예방 또는 치료용 조성물 | |
WO2012046945A2 (ko) | 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물 | |
WO2019216623A1 (ko) | 당뇨병 및 비만 치료용 면역관용 세포 백신 및 인슐린 분비 세포의 제조 방법 | |
WO2022124840A1 (ko) | 해삼 생식선 추출물을 포함하는 조성물, 해삼 난소 추출물로부터 유래된 화합물, 및 이의 용도 | |
WO2018062820A1 (ko) | 피토에스트로겐을 유효성분으로 포함하는 탈모방지 및 모발 성장 촉진용 조성물 | |
WO2015072734A1 (ko) | 사철쑥 유래 스코파론 함유 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 조성물 | |
WO2020080641A1 (ko) | 지노스테마 론기페스 vk1 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 ampk 관련 질환 예방 또는 치료용 조성물 | |
WO2018221922A1 (ko) | 황련 추출물을 함유하는 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2021206455A1 (ko) | 멜리사엽 분획 추출물 및 이를 포함하는 신규한 약학적 조성물 | |
WO2018217009A1 (ko) | 신선초 추출물 또는 이로부터 분리된 화합물을 함유하는 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2010143825A2 (en) | Anti-arthritic agent using cyathula officinalis | |
WO2016048085A1 (ko) | 유효성분의 함량이 향상된 콩 유래 추출물 | |
WO2020256397A1 (ko) | 감초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 | |
WO2011010769A1 (ko) | 실크 펩타이드를 유효성분으로 하는 당뇨 치료 또는 예방용 조성물 | |
WO2021141439A1 (ko) | 커피 실버스킨 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 근육질환의 예방 또는 치료용 조성물 | |
WO2018016901A1 (ko) | 골질환의 예방 또는 치료용 약학적 조성물 | |
WO2022139544A1 (ko) | 아로니아 또는 어성초 추출물을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 | |
WO2021251602A1 (ko) | Phf20을 억제하는 제제를 포함하는 근육 감소로 인한 질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21903885 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18266396 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023559958 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180089989.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21903885 Country of ref document: EP Kind code of ref document: A1 |